Wu Zhi-kui, Liu Yong-mei, Zhang Xin-hua, Liu Wen-jun, Li Min, Wang Rong-xin, Chai Li-min, Wang Wen-juan, Zhang Chong, Huang You-wen, Chen Yu-ying, Lu Xin-xia
Department of Molecular Biology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Zhong Xi Yi Jie He Xue Bao. 2007 Mar;5(2):137-40. doi: 10.3736/jcim20070207.
To investigate the efficacy and safety of Yisui Shengxue Granule (YSSXG), a compound traditional Chinese herbal medicine, in treating beta-thalassemia.
A randomized single-blinded trial was designed. Sixty patients with beta-thalassemia were divided into two groups: 30 patients in YSSXG-treated group and 30 in placebo parallel-control group. The patients in the two groups were assigned to receive either YSSXG or placebo for three months. The patients' symptoms and their blood indexes such as hemoglobin (Hb), red blood cell (RBC), reticulocytes (Ret) and fetal hemoglobin (HBF) were examined before and after the treatment. Meanwhile, the liver and spleen were examined with B-mode ultrasound.
In the YSSXG-treated group, the blood indexes (Hb, RBC, Ret and HBF) and the symptoms of the patients were improved after three-month treatment, with statistical significance compared to those before treatment (P<0.01); hepatauxe and splenomegaly were also relieved (P<0.05) and no adverse reactions were monitored. In the placebo parallel-control group, no significant improvement of the blood indexes and symptoms, as well as the hepatauxe and splenomegaly had been found (P>0.05).
YSSXG demonstrates obvious clinical efficacy and no adverse reactions in treating beta-thalassemia.
探讨复方中药益髓生血颗粒（YSSXG）治疗β地中海贫血的疗效和安全性。
设计一项随机单盲试验。将60例β地中海贫血患者分为两组：益髓生血颗粒治疗组30例，安慰剂平行对照组30例。两组患者分别接受益髓生血颗粒或安慰剂治疗3个月。治疗前后检查患者症状及其血液指标，如血红蛋白（Hb）、红细胞（RBC）、网织红细胞（Ret）和胎儿血红蛋白（HBF）。同时，用B超检查肝脏和脾脏。
益髓生血颗粒治疗组治疗3个月后，患者血液指标（Hb、RBC、Ret和HBF）及症状均有改善，与治疗前比较有统计学意义（P<0.01）；肝肿大和脾肿大也得到缓解（P<0.05），且未监测到不良反应。安慰剂平行对照组血液指标、症状以及肝肿大和脾肿大均无明显改善（P>0.05）。
益髓生血颗粒治疗β地中海贫血临床疗效明显，且无不良反应。
